We would like to gratefully acknowledge financial contributions from the following:

• GlaxoSmithKline
• AstraZeneca Research Foundation India
• Eli Lilly and Company
• The Global Alliance for TB Drug Development

• Chris Dye (World Health Organization, Geneva, Switzerland)
  "The global epidemiology of tuberculosis, and the potential impact of new drugs"
• Rick O'Brien (Centers for Disease Control, Atlanta, USA)
  "The need for new TB drugs: obstacles and opportunities"

• Patrick Brennan (Colorado State University, Ft. Collins, USA)
  "A Multi-Institutional TB Drug Discovery Program Based on Fundamental Principles of Mycobacterium tuberculosis Cell Wall Biosynthesis"
• James Sacchettini (Texas A&M University, USA)
  "Structure-based design of drugs that target enzymes in fatty acid synthesis and degradation"
• John Blanchard (AECOM, USA)
  "Enzymes of Mycobacterial Amino acid and Cofactor Biosynthesis as Potential Targets."
• Issar Smith (Public Health Research Institute, NY)
  "Mycobacterium tuberculosis interactions with host macrophages"

• Kathy Eisenach (University of Arkansas, Little Rock, AK, USA)
  "The use of surrogate markers of drug efficacy in the clinical evaluation of novel antimycobacterial agents"
• Charles Peloquin (National Jewish Hospital, Denver, USA)
  "TB Drug Delivery and Drug Interactions"
• Robert Wallace (UMDNJ Med School, NJ)
  "A whole blood bactericidal assay for tuberculosis"

• Martin Everett (GlaxoSmithKline, UK)
  "Target development and lead identification."
• Denis Mitchison (St. George's Hospital Medical School, London)
  "Selection for sterilising activity"
• Barbara Laughon (NIAID, USA)
  "NIAID screening resources for drug discovery"
• Richard Lee (University of Tennessee, Memphis)
  "Synthesis and evaluation of diamine libraries as new tuberculosis chemotherapies"

• David Russell (Cornell University, USA)
  "Plumbing the environment within the infected phagocyte"
• Joanne Flynn (University of Pittsburgh, USA)
  "The challenges of using animal models to study latent tuberculosis"
• Galina Mukamolova (Bach Institute of Biochemistry, Moscow)
  "Rpg-like growth factors from mycobacterium tuberculosis"

• Jacques Grosset (Groupe Hospitalier Pitie-Salpetriere, Paris)
  "Compared with the standard first line antituberculosis drugs-rifampin, isoniazid, pyrazinamide, streptomycin, ethambutol-, which new drugs have in the mouse model a promising efficacy?"
• Ian Orme (Colorado State University, Ft. Collins, USA)
  "Aerosol infection models for testing drugs in vivo"
• Bala Subramanian (AstraZeneca, India)
  "Efficacy of Anti-TB Compounds:A Pre-Clinical R&D Experience"
• Anthony Hickey (UNC, Chapel Hill)
  "Aerosol delivery of drugs to the lungs: implications for tuberculosis therapy"

• Valerie Mizrahi (South African Instit. Med. Res., Johannesburg, RSA)
  "Acids and fatty acids: Relevance to the mode of action of pyrazinamide"
• William R. Jacobs, Jr. (AECOM, USA)
  "The mechanism of action of isoniazid: A proverb of blind men and an elephant."
• Peter Tonge (SUNY Stony Brook)
  "Mechanism of action of isoniazid"

• Paul Wyatt (GlaxoSmithKline, UK)
  "Thiolactomycin: the rocky road from lead to clinical candidate"
• John Welch (SUNY, Albany, USA)
  "Chemical Modification of Pyrazinamide; A Tool for New Insights into an Old Drug."
• Stephen Gillespie (Royal Free, London)
  "Engineering molecules to solve clinical problems."
• Ramesh Panchagnula (NIPER, India)
  "Rifampicin: revisited"

• Mike Wilson (NIAID, RTB, USA)
  "Microarray platforms and tactics for analyzing gene expression profiles"
• Ruth McAdam (GlaxoSmithKline, UK)
  "Saturation transposon mutagenesis and proteomics to prioritize therapeutic targets in TB"
• Ted Baker (Auckland, New Zealand)
  "From ORFs to protein structures to drugs: a consortium approach to the structural genomics of TB"
• Calvin Boon (Institute of Molecular and Cell Biology, Singapore)
  "Proteins of mycobacterium bovis BCG induced in the Wayne Dormancy Model"